EVO101 Cream for Hidradenitis Suppurativa

Phase < 1

Recruiting

Research Sponsored by Virginia Clinical Research, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥ 18 years at the time of signing the informed consent

Agreement to NOT use topical and/or systemic antibiotics for treatment of HS for the duration of the study

Must not have

Women who are pregnant or breastfeeding

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if drug EVO101 can effectively treat mild to moderate hidradenitis suppurativa in adults. The trial will assess if EVO101 reduces the number of skin lesions

Who is the study for?

Adults with mild to moderate hidradenitis suppurativa, a skin condition that causes small, painful lumps under the skin. Participants must be willing to apply a topical cream, visit the clinic up to five times, and keep a dosing diary over twelve weeks.

What is being tested?

The trial is testing EVO101 topical cream (0.1%) for treating hidradenitis suppurativa. It aims to see if this treatment reduces the number of lesions from first to last visit and improves symptoms based on patient questionnaires.

What are the potential side effects?

Potential side effects are not specified here but may include typical reactions associated with topical creams such as skin irritation, redness, itching or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I agree not to use any antibiotics for HS during the study.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am not pregnant or breastfeeding.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

The efficacy of EVO101 on hidradenitis suppurativa will be evaluated using two parameters: decrease in lesion count and change in patient reported outcomes (PRO)